Remove 2028 Remove Licensing Remove Public Health
article thumbnail

From Discretion to Regulation: What FDA’s Final Rule Means for Laboratory Developed Tests

Hall Render

Stage 4: Effective November 6, 2027 Approximately three and a half years after the publication of the Final Rule, high-risk (Class III) IVDs offered as LDTs must comply with premarket review requirements. The FDA notes that it will continue to exercise enforcement discretion during the review of premarket submissions received by this stage.

FDA 40
article thumbnail

SQA Regulatory Surveillance Summary for May and June 2024

SQA

NPMA Issues Draft Guidelines for Inspection of Medical Device Clinical Trial Sites, 14 June 2024 China NMPA has released a new guideline that aims to enhance the management of clinical trial institutions for medical devices, ensuring compliance with regulatory standards and safeguarding public health.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – March And April

SQA

The deadline for reporting serious incidents not constituting serious public health threats, deaths, or unanticipated serious deteriorations in state of health was reduced to 15 calendar days. The name and address of manufacturers provided by the company on its establishment license application were not accurate.

FDA 40
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

ICMRA recognizes that AMR is a complex, multifaceted problem and calls for better coordination across all sectors, including public health, animal health, and the environment, through a ‘One Health’ approach. Tackling AMR is one of ICMRA’s strategic priorities.

article thumbnail

Healthcare Reforms Under the IRA: Expanding Access to Care

Healthcare Law Blog

After 2026, the timing for publication is standardized – the February 1 st two years prior to the price applicability date will be the drug publication date. Fifteen more Part D drugs are set to be published in 2027, followed by 15 Part D and Part B drugs, collectively, in 2028. Negotiation-Eligible Drugs.

article thumbnail

October-December 2021 State Regulatory Developments

New Jersey Healthcare Blog

Below are the most recent health care related regulatory developments as published in the New Jersey Register from October-December 2021: On October 4, 2021, at 53 N.J.R. 103, which declared a Public Health Emergency for the state in response to COVID-19. Effective September 28, 2028. See N.J.A.C. 10:101 as N.J.A.C.

article thumbnail

Health Provider News

Hall Render

Carolina Neurosurgery & Spine Associates in Charlotte hires new CEO Cone Health could see $1.7B Nursing assistant’s license suspended after arrest, inappropriate relationship with patient R.I.